SCHEMBL2423002

SCHEMBL2423002

O=C(Oc1ccccc1[C@H]1CCC[N]1)N1CCOCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.60
SMN1; SMN2 Q16637 4/20 0.50
POLB P06746 1/20 0.49
BCHE P06276 1/20 0.46
KMT2A Q03164 4/20 0.45
KDM4E B2RXH2 3/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
MAOB P27338 1/20 0.43
MEN1 O00255 1/20 0.43
CASP3 P42574 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
HSD17B10 Q99714 2/20 0.43
EPHX1 P07099 1/20 0.43
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
GAA P10253 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2419710 1.00 TP53 (0.60) TP53SMN1; SMN2POLBBCHEKMT2A
SCHEMBL2421860 0.90 SMN1; SMN2 (0.51) TP53SMN1; SMN2POLBKMT2AKDM4E
SCHEMBL2424506 0.90 SMN1; SMN2 (0.51) TP53SMN1; SMN2POLBKMT2AKDM4E
SCHEMBL2421067 0.90 SMN1; SMN2 (0.51) TP53SMN1; SMN2POLBKMT2AKDM4E
SCHEMBL2172962 0.75 HPGD (0.44) SMN1; SMN2KMT2AKDM4EMEN1HSD17B10
SCHEMBL2173932 0.75 HPGD (0.44) SMN1; SMN2KMT2AKDM4EMEN1HSD17B10
SCHEMBL2175046 0.74 ACHE (0.48) NPC1RAB9AMAOBTSHR
SCHEMBL2422516 0.74 ACHE (0.44) BCHEHSD17B10EPHX1GAAALDH1A1
SCHEMBL2175854 0.74 ACHE (0.48) NPC1RAB9AMAOBTSHR
SCHEMBL2172080 0.74 ACHE (0.44) BCHEHSD17B10EPHX1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853243-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2014-10-07 US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 US disclosed
EP-2264030-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases Incyte Corporation (US) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 TP53 730/4885SMN1; SMN2 4489/4885POLB 1594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.